National security and supply chain security have been the driving political arguments behind the push for the BIOSECURE Act, a bill that would force the separation of the US pharmaceutical industry from certain Chinese manufacturing and contract development companies.
Who Will Reap The BIOSECURE Spoils? US Industry Boost Not Guaranteed
With the BIOSECURE Act halfway to congressional approval, stakeholders are pushing for a financial boost to ensure the US gains the business Chinese companies will lose, but that may be a big lift.
